Skip to main content
GutCited

Lactobacillus reuteri 관련 Bloating and Intestinal Gas

B

Multiple RCTs in breastfed infants show reduced crying time (50-70 min/day reduction). Well-established evidence for infantile colic but limited to infant population.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Dreuteri\u0026condition\u003Dbloating\u002Dand\u002Dgas'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

결론

Multiple RCTs in breastfed infants show reduced crying time (50-70 min/day reduction). Well-established evidence for infantile colic but limited to infant population.

Key Study Findings

basic science
Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA.
Dose: Lactobacillus reuteri E9 (dose not specified) vs: Placebo 효과: None < 0.05
Observational Study n=65 Open-label
Incidence and Characterization of SIBO in NAFLD Patients.
Dose: None vs: None Outcome: SIBO prevalence in NAFLD patients 효과: SIBO in 37%; post-treatment 4% remained+ None

대상 집단: Adults with NAFLD diagnosed via FibroScan

Randomized Controlled Trial n=56 15 weeks Double-blind
Randomised double blind placebo controlled trial on Lactobacillus reuteri DSM 17938: improvement in symptoms and …
Dose: 4x10^8 CFU (induction), 2x10^8 CFU (standard) vs: Placebo Outcome: Constipation symptoms and QoL (Constipaq/CSS) 효과: None pP0.05

대상 집단: Adults with functional constipation

Other n=54 Double-blind
Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, …
Dose: None vs: Simethicone Outcome: Safety and efficacy for functional bloating 효과: None pP0.008

대상 집단: Adults with functional bloating

Meta-Analysis n=3122
Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a …
Dose: None vs: Triple therapy alone/placebo Outcome: H. pylori eradication rate and side effects 효과: None None

대상 집단: Children with H. pylori infection

Randomized Controlled Trial n=101 16 weeks Double-blind
Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, …
Dose: L. reuteri DSM 17938 (1e8 CFU twice daily) vs: placebo Outcome: abdominal pain severity (Wong-Baker FACES) 효과: None None

대상 집단: Children aged 6-15 with functional abdominal pain

Key Statistics

7

연구

500

참여자

Positive

B

등급

Referenced Papers

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

general:
100 million - 5 billion CFU/day
infantilecolic:
100 million CFU/day (DSM 17938 strain, 5 drops)
adultgisupport:
1-5 billion CFU/day

상한량: Well-tolerated up to 10 billion CFU/day in clinical trials

연구에서 사용된 용량

용량 기간 효과 N
Lactobacillus reuteri E9 (dose not specified) -- Positive --
None -- Positive 65
4x10^8 CFU (induction), 2x10^8 CFU (standard) 15 weeks Positive 56
None -- Positive 54
None -- Positive 3122
L. reuteri DSM 17938 (1e8 CFU twice daily) 16 weeks Positive 101
None 4 weeks Positive --

권장 복용 시간: Before meals or on empty stomach; for infants, add drops to breast milk or formula

Safety & Side Effects

보고된 부작용

  • Mild gas in initial days of use
  • Occasional increased fussiness in infants during adjustment (transient)
  • Rare loose stools
  • Very rare: bacteremia in immunocompromised individuals

알려진 상호작용

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (theoretical risk in immunocompromised patients)
  • Proton pump inhibitors (altered gastric pH may affect colonization)

일일 최대 섭취 허용량: Well-tolerated up to 10 billion CFU/day in clinical trials

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does Lactobacillus reuteri help with Bloating and Intestinal Gas?
Based on 7 studies with 500 participants, there is moderate evidence from clinical studies that Lactobacillus reuteri may support Bloating and Intestinal Gas management. Our evidence grade is B (Good Evidence).
How much Lactobacillus reuteri should I take for Bloating and Intestinal Gas?
Studies have used various dosages. A commonly studied range is 100 million - 5 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus reuteri?
Reported side effects may include Mild gas in initial days of use, Occasional increased fussiness in infants during adjustment (transient), Rare loose stools, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus reuteri and Bloating and Intestinal Gas?
We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 500 total participants. The overall direction of effect is positive.

Related Evidence

Lactobacillus reuteri 다른 건강 상태에 대한 근거

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.